TP53BP2 and acute myeloid leukemia: Indeed, we have shown in previous works [9, 10] that attenuation of ASPP1 (PPP1R13B, further ref. to as ASPP1) or ASPP2 (TP53BP2, further ref. to as ASPP2) results in therapy resistance in AML.